Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer’s Nexavar found to improve survival
Based on the DMC’s recommendation, the trial will be stopped to allow all patients to receive treatment with Nexavar. Data from this study will be submitted for presentation
Based on the DMC’s recommendation, the trial will be stopped to allow all patients to receive treatment with Nexavar. Data from this study will be submitted for presentation
The resubmission, based on a pivotal phase III trial, marks the beginning of a six-month review period by the FDA. In September 2006, the company received a complete
Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For prospective pandemic influenza vaccines, reverse genetics can be a
All of the drug candidates under the deal were discontinued or de-prioritized in clinical trials for reasons other than safety, the company said. The agreement provides for payment
Eurand, which developed Amrix for ECR, will now work with Cephalon to support the commercialization of the product in the US. Eurand will receive royalty payments from Cephalon
The double-blind, placebo controlled study will be conducted at sites in the US, South Africa, Eastern Europe and India. The trial is designed to randomly assign approximately 1,200
The drug, Col-118, is a topical formulation that incorporates a compound believed to reduce erythema, a bright skin redness, by constricting enlarged blood vessels in facial tissue. The
Aflibercept is an anti-angiogenic agent targeting vascular endothelial growth factor (VEGF), currently being developed by New York-based Regeneron in collaboration with Sanofi-Aventis. These two trials will be double-blind
The cognitive deficits in schizophrenia (CDS) trial is a double blind, placebo-controlled study being conducted at sites in the US and Canada. The trial design provides for approximately
In addition, the trial showed a 71% reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5% in placebo group and 2.8 percent in